Overview

Key Figures1

kEUR

2021

2020

Change

 

 

 

 

Revenue

282,126

223,033

26.5%

Custom Projects

167,006

101,872

63.9%

Contract Manufacturing

89,600

100,108

-10.5%

Generics & Cosmetics

25,520

21,053

21.2%

EBITDA

84,848

61,923

37.0%

Adjusted 2 EBITDA

88,199

61,958

42.4%

Adjusted 2 EBITDA in % of revenue

31.3%

27.8%

3.5 ppts

Operating result (EBIT)

64,165

44,378

44.6%

Operating result (EBIT) in % of revenue

22.7%

19.9%

2.8 ppts

Result for the year

47,258

31,335

50.8%

Result for the year in % of revenue

16.8%

14.0%

2.7 ppts

Earnings per share (EUR), basic

1.47

1.04

41.0%

Return on net operating assets (RONOA)

21.0%

18.2%

2.7 ppts

Cash and cash equivalents

136,303

17,208

Net cash flow from operating activities

57,352

49,480

15.9%

Capital expenditures

76,652

48,183

59.1%

Capital expenditures in % of revenue

27.2%

21.6%

5.6 ppts

Total assets

595,038

375,975

58.3%

Equity ratio

70.8%

47.3%

23.5 ppts

Employees (# of FTEs, average)

1,041

910

14.4%

1 This table and report include references to operational indicators, such as customer projects, and alternative financial performance measures (APM) that are not defined or specified by IFRS. These APM should be regarded as complementary information to and not as substitutes of the Group’s consolidated financial results based on IFRS. For the definitions of the main operational indicators and APM used, including related abbreviations, as well as for selected reconciliations to IFRS, please refer to the section “Definitions and reconciliations” of this report.

2 Adjusted EBITDA excludes one-off IPO costs of EUR 5.7 million, partly offset by US government loans of EUR 2.4 million waived in context of the coronavirus pandemic.